{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:35:44Z","timestamp":1783488944473,"version":"3.55.0"},"reference-count":26,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2009,9,8]],"date-time":"2009-09-08T00:00:00Z","timestamp":1252368000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2010,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> The effectiveness of Diphencyprone (DPC) in alopecia areata (AA) was demonstrated in several studies with highly variable response rates ranging from 5% to 85%.<\/jats:p><jats:p><jats:bold>Objective\u2002<\/jats:bold> The response rate and variable factors affecting the prognosis were studied focusing on long\u2010term follow\u2010up with or without maintenance therapy.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> A total of 135 cases of AA were treated with DPC. Patients were divided into five groups according to the area of scalp affected: Grade 1 AA: 25\u201349% scalp affection; Grade 2 AA: 50\u201374% scalp affection; Grade 3 AA: 75\u201399% scalp affection; alopecia totalis and alopecia universalis. An initial response was defined as appearance of new terminal hair within treated sites. Excellent response was defined as terminal hair covering &gt;75% of the scalp. Relapse meant &gt;25% hair loss. Maintenance therapy meant ongoing therapy once every 1\u20134\u2003weeks after excellent response. Follow\u2010up was performed to detect any relapse of AA.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Ninety\u2010seven patients continued therapy for \u22653\u2003months. After an initial 3\u2003month lag, cumulative excellent response was seen in 15 patients (15.4%), 47 patients (48.5%), 51 patients (52.6%) and 55 patients (55.7%) after 6, 12, 18 and 24\u2003months respectively in a mean median time of 12\u2003months. The only patient variable affecting the prognosis was baseline extent of AA. Excellent response was seen in 100%, 77%, 54%, 50% and 41% in Grade 1, Grade 2, Grade 3, AA totalis and AA universalis patients respectively. Side\u2010effects were few and tolerable. Hair fall &gt;25% occurred in 17.9% of patients on maintenance and 57.1% of patients without maintenance therapy (<jats:italic>P<\/jats:italic>\u2010value\u2003=\u20030.025).<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> Diphencyprone is an effective and safe treatment of extensive AA. A long period of therapy is needed and will increase the percentage of responders especially in alopecia totalis and universalis. Maintenance therapy is recommended to reduce the risk of relapse.<\/jats:p>","DOI":"10.1111\/j.1468-3083.2009.03401.x","type":"journal-article","created":{"date-parts":[[2009,9,9]],"date-time":"2009-09-09T02:38:31Z","timestamp":1252463911000},"page":"264-269","source":"Crossref","is-referenced-by-count":36,"title":["Five\u2010year experience in the treatment of alopecia areata with DPC"],"prefix":"10.1111","volume":"24","author":[{"given":"BM","family":"El\u2010Zawahry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DA","family":"Bassiouny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Khella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NS","family":"Zaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,2,8]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1978.01640190024007"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(84)80091-2"},{"key":"e_1_2_6_4_2","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1001\/archderm.1987.01660320078016","article-title":"Treatment of alopecia areata with squaric acid dibutylester","volume":"123","author":"Caserio RJ","year":"1987","journal-title":"Arch Dermatol"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.1994.tb00078.x"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1996.119854.x"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1991.tb00443.x"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1991.tb06064.x"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1159\/000249418"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1159\/000017935"},{"key":"e_1_2_6_11_2","first-page":"48","article-title":"Topical Immunotherapy with Diphencyclopropenone in the treatment of chronic extensive alopecia areata","volume":"32","author":"Sotiriadis D","year":"2006","journal-title":"Clinical and Experimetal Dermatology"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1988.tb03230.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(91)70037-3"},{"key":"e_1_2_6_14_2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2340\/00015555634952","article-title":"Diphencyprone in the treatment of alopecia areata","volume":"63","author":"Happle R","year":"1983","journal-title":"Acta Derm Venereol"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(91)70032-W"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1159\/000247540"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1989.tb04166.x"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2004.09.014"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00412926"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12470166"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1159\/000250380"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2001.109309"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1024\/0040-5930.59.5.233"},{"key":"e_1_2_6_24_2","first-page":"1063","article-title":"Predictive model for immunotherapy of alopecia areata with Diphencyprone","volume":"137","author":"Wiseman MC","year":"2001","journal-title":"Arch Dermatol"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.3109\/09546638909086697"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1988.tb03230.x"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-5945-5-6"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-3083.2009.03401.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-3083.2009.03401.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T05:57:24Z","timestamp":1697349444000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-3083.2009.03401.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,8]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["10.1111\/j.1468-3083.2009.03401.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-3083.2009.03401.x","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2,8]]}}}